1
|
Rodak A, Stadlbauer K, Bobbili MR, Smrzka O, Rüker F, Wozniak Knopp G. Development of a Cytotoxic Antibody-Drug Conjugate Targeting Membrane Immunoglobulin E-Positive Cells. Int J Mol Sci 2023; 24:14997. [PMID: 37834445 PMCID: PMC10573690 DOI: 10.3390/ijms241914997] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 10/05/2023] [Accepted: 10/07/2023] [Indexed: 10/15/2023] Open
Abstract
High numbers of membrane immunoglobulin E (IgE)-positive cells are characteristic of allergic conditions, atopic dermatitis, or IgE myeloma. Antibodies targeting the extracellular membrane-proximal domain of the membranous IgE-B-cell receptor (BCR) fragment can be used for specific depletion of IgE-BCR-positive cells. In this study, we derivatized such an antibody with a toxin and developed an antibody-drug conjugate (ADC) that showed strong cytotoxicity for an IgE-positive target cell line. Site-specific conjugation with maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl-monomethyl-auristatin E via a newly introduced single cysteine residue was used to prepare a compound with a drug-antibody ratio of 2 and favorable biophysical properties. The antibody was rapidly taken up by the target cells, showing almost complete internalization after 4 h of treatment. Its cytotoxic effect was potentiated upon cross-linking mediated by an anti-human IgG F(ab')2 fragment. Because of its fast internalization and strict target specificity, this antibody-drug conjugate presents a valuable starting point for the further development of an anti-IgE cell-depleting agent, operating by the combined action of receptor cross-linking and toxin-mediated cytotoxicity.
Collapse
Affiliation(s)
- Aleksandra Rodak
- Institute of Molecular Biotechnology, Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU), Muthgasse 18, 1190 Vienna, Austria; (A.R.); (K.S.); (M.R.B.); (F.R.)
| | - Katharina Stadlbauer
- Institute of Molecular Biotechnology, Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU), Muthgasse 18, 1190 Vienna, Austria; (A.R.); (K.S.); (M.R.B.); (F.R.)
| | - Madhusudhan Reddy Bobbili
- Institute of Molecular Biotechnology, Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU), Muthgasse 18, 1190 Vienna, Austria; (A.R.); (K.S.); (M.R.B.); (F.R.)
- Ludwig Boltzmann Institute for Traumatology, The Research Centre in Cooperation with AUVA, Donaueschingenstraße 13, 1200 Vienna, Austria
| | - Oskar Smrzka
- Ablevia Biotech GmbH, Maria Jacobi Gasse 1, 1030 Vienna, Austria;
| | - Florian Rüker
- Institute of Molecular Biotechnology, Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU), Muthgasse 18, 1190 Vienna, Austria; (A.R.); (K.S.); (M.R.B.); (F.R.)
| | - Gordana Wozniak Knopp
- Institute of Molecular Biotechnology, Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU), Muthgasse 18, 1190 Vienna, Austria; (A.R.); (K.S.); (M.R.B.); (F.R.)
| |
Collapse
|
2
|
Kasper M, Stengl A, Ochtrop P, Gerlach M, Stoschek T, Schumacher D, Helma J, Penkert M, Krause E, Leonhardt H, Hackenberger CPR. Ethynylphosphonamidates for the Rapid and Cysteine‐Selective Generation of Efficacious Antibody–Drug Conjugates. Angew Chem Int Ed Engl 2019. [DOI: 10.1002/ange.201904193] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Marc‐André Kasper
- Chemical Biology Department Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) Robert-Rössle-Strasse 10 13125 Berlin Germany
- Department of Chemistry Humboldt Universität zu Berlin Brook-Taylor-Str. 2 12489 Berlin Germany
| | - Andreas Stengl
- Department of Biology II, and Center for Integrated Protein Science Munich Ludwig-Maximilians-Universität München Großhadenerstr. 2 82152 Martinsried Germany
| | - Philipp Ochtrop
- Chemical Biology Department Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) Robert-Rössle-Strasse 10 13125 Berlin Germany
| | - Marcus Gerlach
- Department of Biology II, and Center for Integrated Protein Science Munich Ludwig-Maximilians-Universität München Großhadenerstr. 2 82152 Martinsried Germany
| | - Tina Stoschek
- Department of Biology II, and Center for Integrated Protein Science Munich Ludwig-Maximilians-Universität München Großhadenerstr. 2 82152 Martinsried Germany
| | - Dominik Schumacher
- Chemical Biology Department Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) Robert-Rössle-Strasse 10 13125 Berlin Germany
- Department of Chemistry Humboldt Universität zu Berlin Brook-Taylor-Str. 2 12489 Berlin Germany
- Department of Biology II, and Center for Integrated Protein Science Munich Ludwig-Maximilians-Universität München Großhadenerstr. 2 82152 Martinsried Germany
| | - Jonas Helma
- Department of Biology II, and Center for Integrated Protein Science Munich Ludwig-Maximilians-Universität München Großhadenerstr. 2 82152 Martinsried Germany
| | - Martin Penkert
- Chemical Biology Department Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) Robert-Rössle-Strasse 10 13125 Berlin Germany
- Department of Chemistry Humboldt Universität zu Berlin Brook-Taylor-Str. 2 12489 Berlin Germany
| | - Eberhard Krause
- Department of Chemistry Humboldt Universität zu Berlin Brook-Taylor-Str. 2 12489 Berlin Germany
| | - Heinrich Leonhardt
- Department of Biology II, and Center for Integrated Protein Science Munich Ludwig-Maximilians-Universität München Großhadenerstr. 2 82152 Martinsried Germany
| | - Christian P. R. Hackenberger
- Chemical Biology Department Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) Robert-Rössle-Strasse 10 13125 Berlin Germany
- Department of Chemistry Humboldt Universität zu Berlin Brook-Taylor-Str. 2 12489 Berlin Germany
| |
Collapse
|
3
|
Kasper MA, Stengl A, Ochtrop P, Gerlach M, Stoschek T, Schumacher D, Helma J, Penkert M, Krause E, Leonhardt H, Hackenberger CPR. Ethynylphosphonamidates for the Rapid and Cysteine-Selective Generation of Efficacious Antibody-Drug Conjugates. Angew Chem Int Ed Engl 2019; 58:11631-11636. [PMID: 31250955 PMCID: PMC6851832 DOI: 10.1002/anie.201904193] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Revised: 05/09/2019] [Indexed: 11/28/2022]
Abstract
Requirements for novel bioconjugation reactions for the synthesis of antibody–drug conjugates (ADCs) are exceptionally high, since conjugation selectivity as well as the stability and hydrophobicity of linkers and payloads drastically influence the performance and safety profile of the final product. We report Cys‐selective ethynylphosphonamidates as new reagents for the rapid generation of efficacious ADCs from native non‐engineered monoclonal antibodies through a simple one‐pot reduction and alkylation. Ethynylphosphonamidates can be easily substituted with hydrophilic residues, giving rise to electrophilic labeling reagents with tunable solubility properties. We demonstrate that ethynylphosphonamidate‐linked ADCs have excellent properties for next‐generation antibody therapeutics in terms of serum stability and in vivo antitumor activity.
Collapse
Affiliation(s)
- Marc-André Kasper
- Chemical Biology Department, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Strasse 10, 13125, Berlin, Germany.,Department of Chemistry, Humboldt Universität zu Berlin, Brook-Taylor-Str. 2, 12489, Berlin, Germany
| | - Andreas Stengl
- Department of Biology II, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-Universität München, Großhadenerstr. 2, 82152, Martinsried, Germany
| | - Philipp Ochtrop
- Chemical Biology Department, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Strasse 10, 13125, Berlin, Germany
| | - Marcus Gerlach
- Department of Biology II, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-Universität München, Großhadenerstr. 2, 82152, Martinsried, Germany
| | - Tina Stoschek
- Department of Biology II, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-Universität München, Großhadenerstr. 2, 82152, Martinsried, Germany
| | - Dominik Schumacher
- Chemical Biology Department, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Strasse 10, 13125, Berlin, Germany.,Department of Chemistry, Humboldt Universität zu Berlin, Brook-Taylor-Str. 2, 12489, Berlin, Germany.,Department of Biology II, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-Universität München, Großhadenerstr. 2, 82152, Martinsried, Germany
| | - Jonas Helma
- Department of Biology II, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-Universität München, Großhadenerstr. 2, 82152, Martinsried, Germany
| | - Martin Penkert
- Chemical Biology Department, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Strasse 10, 13125, Berlin, Germany.,Department of Chemistry, Humboldt Universität zu Berlin, Brook-Taylor-Str. 2, 12489, Berlin, Germany
| | - Eberhard Krause
- Department of Chemistry, Humboldt Universität zu Berlin, Brook-Taylor-Str. 2, 12489, Berlin, Germany
| | - Heinrich Leonhardt
- Department of Biology II, and Center for Integrated Protein Science Munich, Ludwig-Maximilians-Universität München, Großhadenerstr. 2, 82152, Martinsried, Germany
| | - Christian P R Hackenberger
- Chemical Biology Department, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Strasse 10, 13125, Berlin, Germany.,Department of Chemistry, Humboldt Universität zu Berlin, Brook-Taylor-Str. 2, 12489, Berlin, Germany
| |
Collapse
|
4
|
Silver/silver chloride nanoparticles inhibit the proliferation of human glioblastoma cells. Cytotechnology 2018; 70:1607-1618. [PMID: 30203320 DOI: 10.1007/s10616-018-0253-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Accepted: 08/24/2018] [Indexed: 12/31/2022] Open
Abstract
Glioblastomas (GBM) are aggressive brain tumors with very poor prognosis. While silver nanoparticles represent a potential new strategy for anticancer therapy, the silver/silver chloride nanoparticles (Ag/AgCl-NPs) have microbicidal activity, but had not been tested against tumor cells. Here, we analyzed the effect of biogenically produced Ag/AgCl-NPs (from yeast cultures) on the proliferation of GBM02 glioblastoma cells (and of human astrocytes) by automated, image-based high-content analysis (HCA). We compared the effect of 0.1-5.0 µg mL-1 Ag/AgCl-NPs with that of 9.7-48.5 µg mL-1 temozolomide (TMZ, chemotherapy drug currently used to treat glioblastomas), alone or in combination. At higher concentrations, Ag/AgCl-NPs inhibited GBM02 proliferation more effectively than TMZ (up to 82 and 62% inhibition, respectively), while the opposite occurred at lower concentrations (up to 23 and 53% inhibition, for Ag/AgCl-NPs and TMZ, respectively). The combined treatment (Ag/AgCl-NPs + TMZ) inhibited GBM02 proliferation by 54-83%. Ag/AgCl-NPs had a reduced effect on astrocyte proliferation compared with TMZ, and Ag/AgCl-NPs + TMZ inhibited astrocyte proliferation by 5-42%. The growth rate and population doubling time analyses confirmed that treatment with Ag/AgCl-NPs was more effective against GBM02 cells than TMZ (~ 67-fold), and less aggressive to astrocytes, while Ag/AgCl-NP + TMZ treatment was no more effective against GBM02 cells than Ag/AgCl-NPs monotherapy. Taken together, our data indicate that 2.5 µg mL-1 Ag/AgCl-NPs represents the safest dose tested here, which affects GBM02 proliferation, with limited effect on astrocytes. Our findings show that HCA is a useful approach to evaluate the antiproliferative effect of nanoparticles against tumor cells.
Collapse
|
5
|
Ishikawa K, Yoshida K, Kanie K, Omori K, Kato R. Morphology-Based Analysis of Myoblasts for Prediction of Myotube Formation. SLAS DISCOVERY 2018; 24:47-56. [PMID: 30102873 DOI: 10.1177/2472555218793374] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
The development of new drugs depends on the efficiency of drug screening. Phenotype-based screening has attracted interest due to its considerable potency for the discovery of first-in-class drugs. In general, fluorescently labeled imagery is the leading technique for phenotype-based screening; however, there are growing requirements to understand total culture profiles, which are unclear after end-point assays. In this study, we demonstrate that morphology-based cellular evaluation of unlabeled cells is an efficient approach to evaluate myotube formation assays. One of our aims was to study the myogenic differentiation process in C2C12 cells to discern the differences between cellular responses to different medium conditions (serum concentrations and insulin dosages). Our results show that predictive morphological profiles that strongly correlate with myogenic differentiation can be generated from myotube images, even in the confluent stage. The differentiation rate after 14 days can be quantitatively predicted with the highest accuracy by means of images taken on days 0-11.5. In addition, for the application of our morphology-based cellular evaluation, the effect of cyclic guanosine monophosphate (cGMP) on myogenic differentiation was analyzed. Our results show that the quantitated morphological profile from these images can be an effective descriptor for analysis of the myotube-recovering effect of cGMP.
Collapse
Affiliation(s)
- Kiyoshi Ishikawa
- 1 Graduate School of Pharmaceutical Sciences, Nagoya University, Nagoya, Aichi, Japan.,2 Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan
| | - Kei Yoshida
- 1 Graduate School of Pharmaceutical Sciences, Nagoya University, Nagoya, Aichi, Japan
| | - Kei Kanie
- 1 Graduate School of Pharmaceutical Sciences, Nagoya University, Nagoya, Aichi, Japan
| | - Kenji Omori
- 2 Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan
| | - Ryuji Kato
- 1 Graduate School of Pharmaceutical Sciences, Nagoya University, Nagoya, Aichi, Japan
| |
Collapse
|